PRRX1 alterations in liver cancer (i.e. HCC and cholangiocarcinoma) along with its alterations in lung, bladder and breast cancer cohorts, ranked very high (within top 10% of all TCGA cohorts) (Fig. S1B). This evidence concerns the gene PRRX1 and breast cancer.